BACKGROUND: Lung cancer is the leading cancer killer. Early detection will reduce the related deaths. The objective of this study was to identify potential biomarkers for early-stage lung cancer in sputum supernatant. MATERIALS AND METHODS: Using shotgun proteomics, we detected changes in protein profiles that were associated with lung cancer by analyzing sputum supernatants from 6 patients with early-stage lung cancer and 5 cancer-free controls. Using western blotting, we validated the proteomic results in 22 lung cancer cases and 22 controls. Using enzyme-linked immunosorbent assay (ELISA), we evaluated the diagnostic performance of the biomarker candidates in an independent set of 35 cases and 36 controls. RESULTS: Proteomics identified 8 biomarker candidates for lung cancer. Western blotting validation of the candidates showed that enolase 1 (ENO1) displayed a higher expression level in patients with cancer than in cancer-free individuals (P = .015). ELISA revealed that the assessment of ENO1 expression in sputum supernatant had 58.33% sensitivity and 80.00% specificity in distinguishing patients with stage I lung cancer from cancer-free individuals. CONCLUSION: The analysis of protein biomarkers in sputum may provide a potential approach for the early detection of lung cancer. Future validation of all the candidates defined by shotgun proteomics in a large cohort study may help develop additional biomarkers that can be added to ENO1 to provide more diagnostic efficacy for lung cancer.
BACKGROUND:Lung cancer is the leading cancer killer. Early detection will reduce the related deaths. The objective of this study was to identify potential biomarkers for early-stage lung cancer in sputum supernatant. MATERIALS AND METHODS: Using shotgun proteomics, we detected changes in protein profiles that were associated with lung cancer by analyzing sputum supernatants from 6 patients with early-stage lung cancer and 5 cancer-free controls. Using western blotting, we validated the proteomic results in 22 lung cancer cases and 22 controls. Using enzyme-linked immunosorbent assay (ELISA), we evaluated the diagnostic performance of the biomarker candidates in an independent set of 35 cases and 36 controls. RESULTS: Proteomics identified 8 biomarker candidates for lung cancer. Western blotting validation of the candidates showed that enolase 1 (ENO1) displayed a higher expression level in patients with cancer than in cancer-free individuals (P = .015). ELISA revealed that the assessment of ENO1 expression in sputum supernatant had 58.33% sensitivity and 80.00% specificity in distinguishing patients with stage I lung cancer from cancer-free individuals. CONCLUSION: The analysis of protein biomarkers in sputum may provide a potential approach for the early detection of lung cancer. Future validation of all the candidates defined by shotgun proteomics in a large cohort study may help develop additional biomarkers that can be added to ENO1 to provide more diagnostic efficacy for lung cancer.
Authors: Ruedi Aebersold; Leigh Anderson; Richard Caprioli; Brian Druker; Leland Hartwell; Richard Smith Journal: J Proteome Res Date: 2005 Jul-Aug Impact factor: 4.466
Authors: Ruiyun Li; Nevins W Todd; Qi Qiu; Tao Fan; Richard Y Zhao; William H Rodgers; Hong-Bin Fang; Ruth L Katz; Sanford A Stass; Feng Jiang Journal: Clin Cancer Res Date: 2007-01-15 Impact factor: 12.531
Authors: Guoan Chen; Tarek G Gharib; Chiang-Ching Huang; Jeremy M G Taylor; David E Misek; Sharon L R Kardia; Thomas J Giordano; Mark D Iannettoni; Mark B Orringer; Samir M Hanash; David G Beer Journal: Mol Cell Proteomics Date: 2002-04 Impact factor: 5.911
Authors: Gordon MacGregor; Robert D Gray; Thomas N Hilliard; Margaret Imrie; A Christopher Boyd; Eric W F W Alton; Andrew Bush; Jane C Davies; J Alastair Innes; David J Porteous; Andrew P Greening Journal: J Cyst Fibros Date: 2008-02-01 Impact factor: 5.482
Authors: Lingxiao Xing; Jian Su; Maria A Guarnera; Howard Zhang; Ling Cai; Rixin Zhou; Sanford A Stass; Feng Jiang Journal: Clin Cancer Res Date: 2015-01-15 Impact factor: 12.531
Authors: Charles E Birse; Robert J Lagier; William FitzHugh; Harvey I Pass; William N Rom; Eric S Edell; Aaron O Bungum; Fabien Maldonado; James R Jett; Mehdi Mesri; Erin Sult; Elizabeth Joseloff; Aiqun Li; Jenny Heidbrink; Gulshan Dhariwal; Chad Danis; Jennifer L Tomic; Robert J Bruce; Paul A Moore; Tao He; Marcia E Lewis; Steve M Ruben Journal: Clin Proteomics Date: 2015-07-16 Impact factor: 3.988
Authors: Jian Su; Jeipi Liao; Lu Gao; Jun Shen; Maria A Guarnera; Min Zhan; HongBin Fang; Sanford A Stass; Feng Jiang Journal: Oncotarget Date: 2016-02-02